Literature DB >> 22130816

Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease.

L S Howard1.   

Abstract

The practical management of pulmonary arterial hypertension (PAH) requires an accurate assessment of disease severity and prognosis. A number of prognostic indicators are known to be associated with patient outcome, and recent treatment guidelines advocate using such parameters to guide management decisions. Although PAH is characterised by the presence of pulmonary vasculopathy, it is the response of the right ventricle to an increased afterload that is the greatest determinant of a patient's symptoms and survival; thus, measurements that capture right ventricular function provide the best potential to assess PAH severity. One challenge is to understand how the tests we use in everyday clinical practice relate to right heart function in PAH patients, and how current measures can be improved and developed to optimise assessment of disease status and progress. Future research in the field of PAH should focus on how best to assess right heart function, and which measures or combination of measures provide the most relevant information for the individual patient.

Entities:  

Mesh:

Year:  2011        PMID: 22130816     DOI: 10.1183/09059180.00006711

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  26 in total

1.  Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Colm McCabe; Maxine Bennett; Natalie Doughty; Robert MacKenzie Ross; Linda Sharples; Joanna Pepke-Zaba
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

Review 2.  The right ventricle under pressure: evaluating the adaptive and maladaptive changes in the right ventricle in pulmonary arterial hypertension using echocardiography (2013 Grover Conference series).

Authors:  Alexis Harrison; Nathan Hatton; John J Ryan
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

3.  Pulmonary hypertension in rheumatic mitral stenosis revisited.

Authors:  L Pourafkari; S Ghaffari; M Ahmadi; A Tajlil; N Aslanabadi; N D Nader
Journal:  Herz       Date:  2016-12-07       Impact factor: 1.443

4.  D-optimal Design for Preparation and Optimization of Fast Dissolving Bosentan Nanosuspension.

Authors:  Elham Ghasemian; Parisa Motaghian; Alireza Vatanara
Journal:  Adv Pharm Bull       Date:  2016-06-30

Review 5.  Assessment and treatment of the failing right heart: considerations for transplantation referral.

Authors:  Ziad Taimeh
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

6.  A Case Series of Young Patients with Completely Reversed Severe Pulmonary Hypertension.

Authors:  Aniketh Vijay Balegadde; Vikrant Vijan; Rajesh Thachathodiyl
Journal:  J Clin Diagn Res       Date:  2017-05-01

7.  Breath analysis in pulmonary arterial hypertension.

Authors:  Frank S Cikach; Adriano R Tonelli; Jarrod Barnes; Kelly Paschke; Jennie Newman; David Grove; Luma Dababneh; Sihe Wang; Raed A Dweik
Journal:  Chest       Date:  2014-03-01       Impact factor: 9.410

8.  Presence and outcomes of kidney disease in patients with pulmonary hypertension.

Authors:  Sankar D Navaneethan; Edgard Wehbe; Gustavo A Heresi; Varun Gaur; Omar A Minai; Susana Arrigain; Joseph V Nally; Jesse D Schold; Mahboob Rahman; Raed A Dweik
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

9.  Identifying microRNAs targeting Wnt/β-catenin pathway in end-stage idiopathic pulmonary arterial hypertension.

Authors:  Danchen Wu; C Conover Talbot; Qun Liu; Zhi-Cheng Jing; Rachel L Damico; Rubin Tuder; Kathleen C Barnes; Paul M Hassoun; Li Gao
Journal:  J Mol Med (Berl)       Date:  2016-05-18       Impact factor: 4.599

10.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.